Recent Trends in Drug Development and Clinical Trials for Hyperuricemia: A Pharmaprojects-Based Landscape Analysis
7 affiliations
- 1Guang’anmen Hospital Heilongjiang China Academy of Chinese Medical Sciences, Harbin, People’s Republic of China
- 2Jiamusi Hospital of Traditional Chinese Medicine, Jiamusi, People’s Republic of China
- 3Department of Psychology, Brandeis University, Waltham, MA, USA
- 4Department of Rheumatology, Heilongjiang Academy of Traditional Chinese Medicine, Harbin, People’s Republic of China
- 5Department of Geriatrics, Heilongjiang Academy of Traditional Chinese Medicine, Harbin, People’s Republic of China
- 6China Academy of Chinese Medical Sciences, Beijing, People’s Republic of China
- 7Department of Oncology, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, People’s Republic of China
Abstract
Background: Hyperuricemia is increasingly prevalent and is closely associated with gout and several cardiometabolic and renal disorders. Although pharmacological development in this field is expanding, the overall structure and recent evolution of the global development pipeline remain incompletely characterized. This study aimed to characterize recent trends in drug development and clinical research for hyperuricemia.
Methods: Hyperuricemia-related drug-development records were retrieved from the Pharmaprojects database from database inception to July 31, 2025. Records were screened according to disease classification, pharmacological relevance, and development status. After screening and data verification, 69 eligible records were included. Development stage, geographical distribution, therapeutic class, mechanism of action, molecular target, and commencement date were analyzed descriptively.
Results: A total of 69 eligible drug-development records were included. The pipeline was predominantly concentrated in preclinical and early clinical development, with preclinical programs accounting for 31.88%, Phase I for 20.29%, Phase II for 18.84%, and Phase III for 17.39%. China and the United States represented important contributors to the identified development activities. The development portfolio was dominated by gout-related therapies but showed increasing mechanistic diversity. URAT1-related approaches were prominent, and SLC22A12 was the most frequently represented molecular target. Xanthine oxidase-, uricase-, and inflammation-related mechanisms were also represented.
Conclusion: The global development pipeline for hyperuricemia remains weighted toward preclinical and early clinical stages but is becoming increasingly diverse in therapeutic mechanisms and molecular targets. Further late-stage clinical evaluation, multicenter studies, and long-term safety assessment are required to establish the clinical value of emerging therapeutic strategies.
Related
- Clinical Development of Antibacterial Drugs: Recent Progress and Future Outlook.
- Development landscape of ketohexokinase-C (KHK-C) inhibitors for fructose-driven metabolic disorders: from hit discovery to clinical trials.
- Interactions between chronic kidney disease and hyperuricemia in children: mechanisms, clinical manifestations and management updates
- Clinical development landscape of CAR/TCR-engineered cellular therapies in musculoskeletal sarcomas: a TrialTrove-based registry analysis
- Hyperuricemia in Chronic Kidney Disease: Clinical Evidence and the Missing Role of Urinary Uric Acid Handling
BibTeX
@article{zhang2026recent,
title = {{Recent Trends in Drug Development and Clinical Trials for Hyperuricemia: A Pharmaprojects-Based Landscape Analysis}},
author = {Hu Zhang and Senyue Zhang and Tong Fu and Mingzhu Zhang and Cunyue Yu and Jianing Li and Ying Tong},
journal = {Pharmacogenomics and Personalized Medicine},
year = {2026},
month = oct,
doi = {10.2147/pgpm.s602618},
url = {https://doi.org/10.2147/pgpm.s602618},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Recent Trends in Drug Development and Clinical Trials for Hyperuricemia: A Pharmaprojects-Based Landscape Analysis
AU - Hu Zhang
AU - Senyue Zhang
AU - Tong Fu
AU - Mingzhu Zhang
AU - Cunyue Yu
AU - Jianing Li
AU - Ying Tong
PY - 2026
DA - 2026/10/30
JO - Pharmacogenomics and Personalized Medicine
DO - 10.2147/pgpm.s602618
UR - https://doi.org/10.2147/pgpm.s602618
AB - Background: Hyperuricemia is increasingly prevalent and is closely associated with gout and several cardiometabolic and renal disorders. Although pharmacological development in this field is expanding, the overall structure and recent evolution of the global development pipeline remain incompletely characterized. This study aimed to characterize recent trends in drug development and clinical research for hyperuricemia. Methods: Hyperuricemia-related drug-development records were retrieved from the Pharmaprojects database from database inception to July 31, 2025. Records were screened according to disease classification, pharmacological relevance, and development status. After screening and data verification, 69 eligible records were included. Development stage, geographical distribution, therapeutic class, mechanism of action, molecular target, and commencement date were analyzed descriptively. Results: A total of 69 eligible drug-development records were included. The pipeline was predominantly concentrated in preclinical and early clinical development, with preclinical programs accounting for 31.88%, Phase I for 20.29%, Phase II for 18.84%, and Phase III for 17.39%. China and the United States represented important contributors to the identified development activities. The development portfolio was dominated by gout-related therapies but showed increasing mechanistic diversity. URAT1-related approaches were prominent, and SLC22A12 was the most frequently represented molecular target. Xanthine oxidase-, uricase-, and inflammation-related mechanisms were also represented. Conclusion: The global development pipeline for hyperuricemia remains weighted toward preclinical and early clinical stages but is becoming increasingly diverse in therapeutic mechanisms and molecular targets. Further late-stage clinical evaluation, multicenter studies, and long-term safety assessment are required to establish the clinical value of emerging therapeutic strategies.
SN - 1178-7066
ER -